Vyne Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

YARROW BIOSCIENCE

10/11/2022 22:02

* Vyne Therapeutics Inc  VYNE.OQ  reported a quarterly
adjusted
loss of 16 cents​​ per share for the quarter ended in September.
The mean expectation of four analysts for the quarter was for a
loss of 17 cents per share.
    * Revenue fell 95.9% to $167.00 thousand from a year ago;
analysts
expected $133.33 thousand. 
    * The mean earnings estimate of analysts had risen by
about 8.8%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Vyne Therapeutics Inc shares had risen by 10.4% this
quarter and
lost 75.9% so far this year.
    * The company reported a quarterly loss of $9.46 million.
    * Wall Street's median 12-month price target for Vyne
Therapeutics
Inc is $4.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
10 at 10:02 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.17          -0.16          Beat
 Jun. 30 2022      -0.17          -0.13          Beat
 Mar. 31 2022      -0.16          -0.14          Beat
 Dec. 31 2021      -0.24          -0.20          Beat